Fatal hepatic vascular toxicity of DTIC. Is it really a rare event?

Abstract

A fatal massive hepatic necrosis with widespread thrombotic occlusion of the small hepatic veins developed in two of 68 patients treated with DTIC for advanced melanoma in a randomized study. Thirteen similar reactions, in patients treated with single-agent DTIC, are reported in the literature. Several clinical and pathologic features distinguish this DTIC toxicity from Budd-Chiari syndrome and veno-occlusive disease (both well-known types of possibly drug-related hepatic vascular disease) and make it a distinctive syndrome. We were impressed by the repeated occurrence of this complication in a relatively small set of patients, in contrast with the rarity of the literature reports. We suggest that this dramatic complication could occur more frequently than commonly thought. Therefore, caution should be used with DTIC, particularly in curable patients.

• Authors: G Ceci, M Bella, M Melissari, M Gabrielli, P Bocchi, G Cocconi
• Journal: Cancer (Cancer) Vol. 61 Issue 10 Pg. 1988-91 (May 15 1988) ISSN: 0008-543X [Print] United States
• PMID: 3359400 (Publication Type: Case Reports, Journal Article)

Chemical References

• Dacarbazine

Topics

• Aged
• Budd-Chiari Syndrome (chemically induced, pathology)
• Combined Modality Therapy
• Dacarbazine (adverse effects, therapeutic use)
• Eosinophilia (chemically induced)
• Fever (chemically induced)
• Humans
• Male
• Melanoma (complications, drug therapy, surgery)
• Middle Aged
• Necrosis
• Skin Neoplasms (complications, drug therapy, surgery)